Article Text
Abstract
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ deposition, one of the neuropathological hallmarks of Alzheimer’s disease. There is increasing evidence to support its clinical utility, with major studies showing that amyloid PET imaging improves diagnostic accuracy, increases diagnostic certainty and results in therapeutic changes. The Amyloid Imaging Taskforce has developed appropriate use criteria to guide clinicians by predefining certain scenarios where amyloid PET would be justified. This review provides a practical guide on how and when to use amyloid PET, based on the available research and our own experience. We discuss its three main appropriate indications and illustrate these with clinical cases. We stress the importance of a multidisciplinary approach when deciding who might benefit from amyloid PET imaging. Finally, we highlight some practical points and common pitfalls in its interpretation.
- ALZHEIMER’S DISEASE
- AMYLOID
- BEHAVIOURAL DISORDER
- VISUAL ATTENTION
- ATTENTION
- COGNITIVE NEUROPSYCHOLOGY
- COGNITION
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients
- Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance
- Brain imaging in dementia
- Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
- Biomarkers in dementia: clinical utility and new directions
- Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- Retinal imaging in Alzheimer’s disease
- CSF biomarkers for dementia
- Biomarkers for the diagnosis of Alzheimer’s disease, dementia Lewy body, frontotemporal dementia and vascular dementia